Compound information
- Natural Products
- NACP133430
- Molecular Formula
- C20H32O3
- Molecular Weight
- 320.235144884 g/mol
- Structure
-
- IUPAC Name
- 5-oxoicosa-6,8,11-trienoic acid
- InChI
- InChI=1S/C20H32O3/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-16-19(21)17-15-18-20(22)23/h9-10,12-14,16H,2-8,11,15,17-18H2,1H3,(H,22,23)
- InChI Key
- ULMVEQWNDGUUBR-UHFFFAOYSA-N
- SMILES
- O=C(O)CCCC(=O)C=CC=CCC=CCCCCCCCC
- CAS
- SuperClass
- Lipids and lipid-like molecules
- Class
- Fatty Acyls
- SubClass
- Fatty acids and conjugates
- Source
- CNP0261886
Warheads
- Michael Acceptor
-
ADMET Property
Physicochemical Property
| Property | Value | Property | Value |
|---|---|---|---|
| Heavy Atom Count | 23 | Ring Count | 0 |
| Heteroatom Count | 3 | Rotatable Bond Count | 15 |
| Hydrogen Bond Acceptor Count | 2 | Hydrogen Bond Donor Count | 1 |
| Topological Polar Surface Area | 54.37 Å2 | LogP | 5.792 |
| LogS | -4.602 | LogD | 3.809 |
Absorption
| Property | Value | Property | Value |
|---|---|---|---|
| Pgp inhibitor | 0.354 | Pgp substrate | 0.001 |
| HIA | 0.973 | F20 % | 0.988 |
| F30 % | 0.409 | Caco-2 | -4.674 |
| MDCK | -4.54 |
Distribution
| Property | Value | Property | Value |
|---|---|---|---|
| BBB Penetration | 0.957 | PPB | 85.054 |
| VD | 0.599 | Fu | 1.845 |
Metabolism
| Property | Value | Property | Value |
|---|---|---|---|
| CYP1A2 inhibitor | 0.887 | CYP1A2 substrate | 0.288 |
| CYP2A6 substrate | 0.319 | CYP2B6 substrate | 0.424 |
| CYP2C19 inhibitor | 0.051 | CYP2C19 substrate | 0.302 |
| CYP2C8 substrate | 0.506 | CYP2C9 inhibitor | 0.666 |
| CYP2C9 substrate | 0.029 | CYP2D6 inhibitor | 0.248 |
| CYP2D6 substrate | 0.146 | CYP2E1 substrate | 0.246 |
| CYP3A4 inhibitor | 0.109 | CYP3A4 substrate | 0.018 |
Excretion
| Property | Value | Property | Value |
|---|---|---|---|
| T1/2 | 0.83 | CL | 2.798 |
Toxicity
| Property | Value | Property | Value |
|---|---|---|---|
| hERG Blockers | 0.589 | Hepatotoxicity | 0.805 |
| Mutagenicity | 0.038 | Rat Oral Acute Toxicity | 0.011 |
| FDAMDD | 0.566 | Skin Sensitization | 0.995 |
| Carcinogenicity | 0.845 | Eye Corrosion | 0.109 |
| Eye Irritation | 0.942 | Respiratory Toxicity | 0.401 |
Environmental Toxicity
| Property | Value | Property | Value |
|---|---|---|---|
| Bioconcentration Factors | 0.852 | IGC50 | 4.518 |
| LC50FM | 5.469 | LC50DM | 6.059 |
Tox21 Pathway
| Property | Value | Property | Value |
|---|---|---|---|
| NR-AR | 0.264 | NR-AR-LBD | 0.373 |
| NR-AhR | 0.003 | NR-Aromatase | 0.073 |
| NR-ER | 0.276 | NR-ER-LBD | 0.351 |
| NR-PPAR-gamma | 0.905 | SR-ARE | 0.892 |
| SR-ATAD5 | 0.361 | SR-HSE | 0.818 |
| SR-MMP | 0.036 | SR-p53 | 0.631 |
Similar covalent inhibitors
Similar covalent drugs
No similar covalent drugs found for this compound.